NCT01503840View on ClinicalTrials.gov

Evaluation of Accelerometer-Based Neuromuscular Monitoring Reliability to Exclude Postoperative Residual Paralysis

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

June 30, 2012

Study Completion Date

July 31, 2012

Conditions
Postoperative Residual Paralysis
Interventions
DRUG

sugammadex

sugammadex 10 mg/ml diluted solution dosage: 1mg/kg i.v. (0,1 ml/kg)

DRUG

Sodium chloride solution

Sodium chloride solution 0,9% dosage: 0,1 ml/kg i.v.

Trial Locations (1)

Unknown

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

All Listed Sponsors
lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER

NCT01503840 - Evaluation of Accelerometer-Based Neuromuscular Monitoring Reliability to Exclude Postoperative Residual Paralysis | Biotech Hunter | Biotech Hunter